Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box only protein 50 (FBXO50, formerly known as NCCRP1) is a member of the F-box protein family involved in E3 ubiquitin ligase complexes, with a recognized F-box-associated (FBA) domain and evolutionary relationships to lectin-type F-box proteins[1][2][5]. FBXO50 is predominantly cytosolic and is implicated in protein-protein interactions that facilitate the ubiquitination and subsequent proteasomal degradation of specific substrates, particularly glycoproteins, although its lectin activity has yet to be experimentally confirmed[1][2][3]. In fish and mammals, the protein is expressed in nonspecific cytotoxic cells, where it is thought to contribute to their cytolytic activity[1][2]. Its expression is upregulated in specific pathological contexts, most notably in carbonic anhydrase IX-deficient mice, suggesting roles in cell proliferation and possibly tumorigenesis[1][3]. FBXO50 contains an FBA domain and shares homology with other FBXO family lectin-type proteins but possesses a structurally truncated F-box domain in mammals compared to canonical members[1][2][5]. No currently approved drugs or clinical biomarkers are reported that target FBXO50 directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on F-box only protein 50 (FBXO50).